# South America Dry Age Related Macular Degeneration Market

> South America Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.52%
- **2024:** $ 380.8 Million
- **2025:** $ 412.4 Million
- **2035:** $ 845.6 Million
- **Key Players:** Novartis (CH), Roche (CH), Regeneron Pharmaceuticals (US), Bayer (DE), Allergan (IE), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US)

**Report ID:** MRFR/LS/43220-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-dry-age-related-macular-degeneration-market-44900

---

## Market Summary

## **South America Dry Age-Related Macular Degeneration (AMD) Market Overview**

As per MRFR analysis, the South America Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 440.0 (USD Million) in 2023. The South America Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 480.0(USD Million) in 2024 to 1,095.0 (USD Million) by 2035. The South America Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 7.786% during the forecast period (2025-2035).

**Key South America Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted**

The South America Dry Age-Related Macular Degeneration (AMD) market is experiencing notable trends driven largely by the increasing aging population within the region. Countries like Brazil and Argentina are witnessing a rise in elderly individuals, leading to a higher prevalence of age-related eye diseases. Additionally, awareness campaigns focused on the importance of early diagnosis and prevention are gaining traction. These initiatives are supported by both government health organizations and non-profit groups aiming to educate the public about AMD and its management.

Opportunities in the South America Dry AMD market are being explored as there is a growing interest among pharmaceutical companies to develop innovative therapies and advanced treatment options tailored for the regional demographics. The need for efficient anti-AMD treatments will require investment in research and development. Specialists targeting low-serviced locations have a tremendous opportunity if they are willing to tackle the challenges posed by local healthcare systems. The trends show that personalized medicine is starting to penetrate into the market.

There is an increasing acceptance by doctors of a move towards bespoke treatment regimens driven by the patient's genetic makeup and their way of living. In addition, the use of digital health services like telemedicine and health for monitoring and treatment of AMD is growing, especially in areas where specialists are scarce.

Given the diverse population and varied healthcare challenges in South America, these developments are crucial in addressing the unique needs of patients suffering from Dry AMD in the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America Dry Age-Related Macular Degeneration (AMD) Market Drivers**

**Increasing Aging Population**

The South America Dry Age-Related Macular Degeneration (AMD) Market Industry is significantly driven by the increasing aging population in the region. Data from regional demographic studies indicate that the population aged 65 and older in South America is projected to rise from approximately 9% in 2020 to about 13% by 2035. This demographic shift is driven by improved healthcare access and life expectancy.

Organizations like the Pan American Health Organization (PAHO) have highlighted the need for enhanced healthcare systems to support the growing number of elderly individuals, many of whom are at higher risk for age-related conditions such as AMD.Consequently, the rising aged demographic is expected to lead to a greater demand for AMD-related healthcare solutions and treatments, subsequently propelling market growth in the coming years. As the healthcare system evolves to meet these needs, the South America Dry Age-Related Macular Degeneration (AMD) Market is predicted to expand.

**Increased Awareness and Screening Programs**

In South America, there has been a notable increase in public awareness regarding eye health, particularly related to dry AMD. Various public health campaigns and initiatives spearheaded by healthcare authorities and organizations are promoting early detection and regular eye screenings.

For instance, the Brazilian Ministry of Health has launched programs aimed at educating the public on the risks of AMD and the importance of regular eye examinations, which is projected to increase screenings by over 30% in the next five years.This rise in screenings will likely lead to earlier diagnoses, driving demand for AMD treatments and resources in the South America Dry Age-Related Macular Degeneration (AMD) Market Industry.

**Advancements in Treatment Options**

The South America Dry Age-Related Macular Degeneration (AMD) Market is experiencing growth fueled by advancements in treatment options. Novel therapies, such as anti-VEGF injections and nutritional supplements like AREDS formulations, are being increasingly introduced in the region. Research from pharmaceutical organizations indicates that innovative treatments may reduce the progression of AMD by over 25% when started early.

The Brazilian Society of Ophthalmology has emphasized the importance of adopting these advanced treatment protocols in clinical practice.As healthcare providers become more equipped to offer these treatments, the demand in the South America Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to rise in response.

**South America Dry Age-Related Macular Degeneration (AMD) Market Segment Insights**

**Dry Age-Related Macular Degeneration (AMD) Market Stage Insights**

The South America Dry Age-Related Macular Degeneration (AMD) Market is witnessing substantial growth, driven by the increasing prevalence of age-related eye diseases among the aging population. Within the market, the Stage segment plays a pivotal role, as it encompasses various classifications of AMD that determine the severity and treatment approaches. Early age-related macular degeneration is often characterized by subtle vision changes and is critical for intervention strategies, as early diagnosis can lead to better management and improved quality of life for patients. This segment is essential in the realm of preventive care, emphasizing regular eye examinations for the elderly population.

Intermediate age-related macular degeneration tends to show more pronounced symptoms, including blurred vision or difficulty in recognizing faces. This stage represents a significant focus for healthcare professionals, as it signals a transition to more severe deterioration and highlights the urgency for effective therapeutic measures. Innovative treatment options are continually emerging in this space, aiming to slow down the progression of the disease. Late age-related macular degeneration is particularly concerning, as it affects a substantial part of the visual field and can lead to irreversible vision loss.

This stage is crucial in understanding the broader implications for public health, as it increases the burden on healthcare systems and impacts the quality of life for numerous patients. As a result, the South America Dry Age-Related Macular Degeneration (AMD) Market is poised to develop new therapies and preventive measures. Overall, the Stage segment's insights are foundational for developing targeted strategies and treatments, demonstrating the critical need for awareness and research in addressing AMD across different age groups in South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights**

The Age Group segment within the South America Dry Age-Related Macular Degeneration (AMD) Market showcases significant insights into the demographics affected by this condition. Individuals above 75 years represent a critical population due to the higher prevalence of AMD in older adults, often serving as a focal point for healthcare resources and treatments. This age group is increasingly recognizing the importance of early diagnosis and management of AMD, which drives market demand for innovative therapeutic options.

The demographic above 60 years also plays a vital role, as awareness campaigns are prevalent in this bracket, which continues to grow due to the aging population in South America. The above 40 years age group is emerging prominently with a rising incidence of early AMD manifestations, leading to early intervention strategies and preventive measures gaining traction. The market growth in South America is particularly influenced by an increased life expectancy, which correlates with a higher number of individuals experiencing age-related eye conditions.

Overall, the Age Group segmentation reveals critical behavioral trends, challenges, and opportunities that shape the South America Dry Age-Related Macular Degeneration (AMD) Market industry.

**Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights**

The Diagnosis and Treatment segment of the South America Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in addressing this prevalent condition that significantly impacts vision among the aging population. The emphasis on early diagnosis is essential, as timely detection can lead to effective management and improved patient outcomes. The market for treatment options is expanding rapidly, driven by the increasing incidence of dry AMD, which is associated with significant visual impairment and a declining quality of life.

Innovations in treatment methods, including advanced pharmaceuticals and laser therapies, are shaping the market landscape.Countries in South America are witnessing a rising awareness and education regarding AMD, which contributes to growth within this segment. Moreover, collaborations between healthcare providers and research institutions are enabling the development of more effective diagnostic tools and treatment protocols. However, challenges such as access to healthcare facilities and affordability of treatments remain pertinent.

Nonetheless, growing investment in healthcare infrastructure poses considerable opportunities for expanding the reach of diagnosis and treatment solutions, improving overall market dynamics in the region.As the population ages, the significance of this segment in the South America Dry Age-Related Macular Degeneration (AMD) Market is set to increase, reflecting an ongoing commitment to improving eye health for millions.

**Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights**

The Route of Administration segment within the South America Dry Age-Related Macular Degeneration (AMD) Market is crucial as it influences the effectiveness and patient adherence to treatment modalities. This market segment showcases a significant division between oral therapies and injectable treatments.

Oral administration is valued for its convenience and ease of use, appealing particularly to the older demographic often affected by AMD, while injectables are acknowledged for delivering medications more directly and efficiently to the eye, thereby enhancing therapeutic outcomes.As the population continues to age, the demand for effective and user-friendly treatment options in South America is expected to grow, fostering innovations in drug formulations and delivery mechanisms. This evolving landscape is driven by the rising prevalence of AMD and the urgent need for effective management solutions.

Regulatory frameworks and healthcare infrastructure improvements further support the expansion of this market segment, aligning with regional health initiatives aimed at improving eye health and reducing the burden of visual impairment.Such dynamics enable the Route of Administration segment to play a pivotal role in addressing the needs of AMD patients and contribute significantly to the overall market’s growth potential.

**Dry Age-Related Macular Degeneration (AMD) Market End Users Insights**

The South America Dry Age-Related Macular Degeneration (AMD) Market showcases a diverse array of end users, significantly shaping its landscape. Hospitals and clinics serve as primary facilitators, providing direct patient care and essential treatment protocols that cater to the rising prevalence of AMD in the aging population, estimated at around 13% in South America, thus highlighting their pivotal role in the healthcare system. Diagnostic centers contribute by facilitating early detection through advanced imaging technologies, enabling timely interventions that can slow disease progression.Their emphasis on accurate diagnostics directly influences patient outcomes, which is increasing demand for such specialized services.

Furthermore, academic and research institutes are crucial for cultivating innovative treatment approaches and training healthcare professionals in the region. The growing investment in research reflects a commitment to addressing AMD challenges while also fostering collaborations that enhance the overall medical expertise available in South America. Each of these end users plays a significant role in the AMD market ecosystem, collectively driving advancements that improve patient care and health outcomes within the region.

**South America Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights**

The South America Dry Age-Related Macular Degeneration (AMD) Market presents a dynamic and competitive landscape characterized by various players striving to address the growing prevalence of AMD in the region. Market insights reveal that several companies are focusing on enhancing treatment options through innovative research and development efforts. As the population ages and awareness about eye health increases, demand for effective solutions to manage AMD is expected to rise significantly. This trend drives companies to create specialized products targeting AMD management, incorporating advanced technology and novel therapeutics.

The competition is not only among pharmaceutical giants but also includes emerging firms seeking to carve a niche in this vital therapeutic area. Companies involved in this market are compelled to improve their service delivery, product effectiveness, and patient outcomes to maintain a competitive edge.Bayer has positioned itself as a strong player in the South America Dry Age-Related Macular Degeneration (AMD) Market, driven by its commitment to research and development as well as its robust marketing strategies. The company's expertise in ophthalmology is reflected in its innovative product offerings tailored to meet the specific needs of the South American demographic.

Bayer's established presence in the region allows for a more profound understanding of local healthcare practices and regulatory frameworks. With a well-distributed network and partnerships with healthcare providers, Bayer ensures that its treatments reach patients effectively. The company's focus on patient education and awareness campaigns further strengthens its position in the market, enabling them to connect better with the communities they serve.Genentech, recognized for its pioneer work in biopharmaceuticals, has made significant inroads into the South America Dry Age-Related Macular Degeneration (AMD) Market. The company's emphasis on groundbreaking therapies, particularly in areas of retinal diseases, positions it favorably against competitors.

Genentech's portfolio includes key products designed specifically for AMD management, which enhance patient outcomes while focusing on safety and efficacy. The company's presence is bolstered by strategic mergers and acquisitions that expand its capabilities and enhance its research infrastructure within the region. By leveraging local partnerships and relationships with health providers, Genentech ensures that its offerings are accessible to patients in South America, thereby improving health outcomes. Their commitment to understanding regional medical needs drives the development of targeted therapies that reflect the evolving landscape of AMD treatment in South America.

**Key Companies in the South America Dry Age-Related Macular Degeneration (AMD) Market Include**

**South America Dry Age-Related Macular Degeneration (AMD) Market Industry Developments**

Recent developments in the South America Dry Age-Related Macular Degeneration (AMD) Market have been significant as companies like Bayer, Genentech, and Novartis continue to focus on innovative treatment solutions. In August 2023, Bayer launched a new initiative aimed at increasing awareness and diagnosis of AMD in the region, particularly in Brazil and Argentina, where incidence rates are markedly high. Additionally, Roche's commitment to research and development has led to promising clinical trials for new therapies targeting dry AMD, showcasing their potential to enhance patient outcomes.

In terms of mergers and acquisitions, Novartis announced in July 2023 their acquisition of a smaller biotech firm focused on ocular treatments, which is anticipated to strengthen its portfolio within the AMD sector. Over the past couple of years, there has been notable growth in market valuation as investments in AMD treatment technologies have surged, reflecting increasing demand for effective therapies. This growth trend has been particularly evident in countries with aging populations, such as Chile and Uruguay, further driving interest from pharmaceutical companies and investors alike.

**South America Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights**

## Market Drivers

### Rising Aging Population

The South America Dry [Age Related Macular Degeneration](https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736) Amd Market is significantly influenced by the increasing aging population across the region. As life expectancy rises, the number of individuals aged 65 and older is projected to grow substantially. This demographic shift is particularly pronounced in countries like Brazil and Argentina, where the elderly population is expected to double by 2050. Consequently, the prevalence of age-related diseases, including AMD, is likely to escalate, thereby driving demand for diagnostic and therapeutic solutions. The South America Dry Age Related Macular Degeneration Amd Market must adapt to this demographic trend by enhancing accessibility to treatments and ensuring that healthcare systems are equipped to manage the growing patient population.

### Growing Healthcare Expenditure

The South America Dry Age Related Macular Degeneration Amd Market is also driven by the rising healthcare expenditure in the region. As economies in South America continue to develop, there is a noticeable increase in healthcare budgets, which allows for better allocation of resources towards eye care services. Countries like Chile and Colombia are investing in advanced medical technologies and training healthcare professionals to manage AMD effectively. This growing investment in healthcare infrastructure is expected to enhance the availability of diagnostic and treatment options for AMD, thereby fostering market growth and improving patient outcomes.

### Government Initiatives and Funding

Government initiatives aimed at combating age-related diseases are crucial for the South America Dry Age Related Macular Degeneration Amd Market. Various South American governments have recognized the need to address the rising burden of AMD and are implementing policies to enhance healthcare infrastructure. For example, Brazil's Ministry of Health has allocated funding for eye health programs, which include screening and treatment for AMD. Such initiatives not only improve access to care but also raise awareness about the disease. Increased government support is likely to stimulate market growth by facilitating research and development of new therapies and ensuring that patients receive timely interventions.

### Technological Innovations in Treatment

Technological advancements play a pivotal role in shaping the South America Dry Age Related Macular Degeneration Amd Market. Recent innovations in treatment modalities, such as anti-VEGF therapies and [photodynamic therapy](https://www.marketresearchfuture.com/reports/photodynamic-therapy-market-43193), have shown promising results in managing AMD. For instance, the introduction of new drug formulations and delivery systems has improved patient outcomes and compliance. Moreover, the integration of telemedicine and digital health solutions is enhancing patient monitoring and follow-up care. As these technologies become more prevalent, they are expected to drive market growth by providing more effective and accessible treatment options for patients suffering from AMD in South America.

### Increased Collaboration Among Stakeholders

Collaboration among various stakeholders, including healthcare providers, pharmaceutical companies, and non-profit organizations, is emerging as a key driver for the South America Dry Age Related Macular Degeneration Amd Market. Partnerships aimed at research, education, and awareness campaigns are becoming more common. For instance, joint initiatives between local health authorities and international organizations are focusing on improving AMD screening and treatment access. Such collaborations not only enhance the distribution of resources but also promote knowledge sharing and best practices in managing AMD. This collective effort is likely to strengthen the market by ensuring that patients receive comprehensive care and support.

## Future Outlook

The South America Dry Age Related Macular Degeneration market is projected to grow at a 7.52% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options.

**New opportunities:**

- Development of telemedicine platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905)
- Investment in AI-driven diagnostic tools for early detection
- Expansion of specialized clinics focusing on AMD treatment and management

By 2035, the market is expected to be robust, driven by innovation and increased patient access.

## Segment Insights

### By Application: Therapeutic Intervention (Largest) vs. Clinical Diagnosis (Fastest-Growing)

In the South America Dry Age Related Macular Degeneration Amd Market, the application segment is primarily divided among Therapeutic Intervention, Clinical Diagnosis, Research and Development, and Patient Monitoring. Therapeutic Intervention holds the largest market share due to its critical role in addressing the needs of patients suffering from AMD, thereby driving substantial investment and focus within healthcare facilities. Meanwhile, Clinical Diagnosis is emerging rapidly, fueled by increasing awareness and advancements in diagnostic technologies that enhance early detection and treatment planning.

Therapeutic Intervention: Largest vs. Clinical Diagnosis: Fastest-Growing

Therapeutic Intervention is characterized by its established methodologies and a variety of treatment options available for AMD, making it the backbone of patient care in this sector. The extensive adoption of pharmacologic treatments and laser therapies drives its dominance. Conversely, Clinical Diagnosis is witnessing transformative growth as the integration of artificial intelligence and imaging technologies enhances accuracy and speed in diagnosing AMD. This not only improves patient outcomes but also encourages healthcare providers to adopt these innovations, positioning Clinical Diagnosis as an increasingly pivotal part of AMD management.

### By End User: Hospitals (Largest) vs. Ophthalmology Clinics (Fastest-Growing)

In the South America Dry Age Related Macular Degeneration AMD market, the distribution of market share among end users reveals hospitals as the largest segment. Hospitals account for the majority of patient treatments due to their comprehensive facilities and numerous resources for managing advanced stages of AMD. Conversely, ophthalmology clinics are gaining traction, emerging as the fastest-growing segment as they provide specialized care tailored to AMD patients. Their focus on diagnostic technologies and individual attention appeals to a growing demand for personalized treatment options.
Growth trends in this segment show a marked increase in the utilization of specialized services offered by ophthalmology clinics. Driving factors include rising awareness about AMD among the population and the importance of early diagnosis and treatment. As more individuals seek targeted care, the shift towards outpatient services at clinics is expected to accelerate, thereby enhancing their market position alongside traditional hospital settings.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals in South America play a dominant role in the AMD market, equipped with state-of-the-art technology, specialized personnel, and comprehensive treatment protocols. Their established patient base and extensive networks allow them to provide a full spectrum of care, from diagnosis to advanced surgical interventions. In contrast, research institutions are emerging as vital players, focusing on innovative treatment options and clinical trials that can lead to significant advancements in AMD care. These institutions are crucial for furthering research on prevention and treatment methodologies, thus contributing to the overall landscape of AMD management. As they develop new therapies and conduct trials, their influence and market presence are steadily growing, positioning them as essential contributors to the future of AMD treatment.

### By Type of Treatment: Pharmacological (Largest) vs. Nutritional Supplementation (Fastest-Growing)

In the South America Dry Age Related Macular Degeneration (AMD) market, the 'Type of Treatment' segment showcases a diverse distribution among its values. 'Pharmacological' treatments hold the largest market share, providing established and effective solutions to mitigate the effects of dry AMD. 'Surgical' options, while crucial, represent a smaller portion of the market compared to pharmacological approaches. 'Nutritional Supplementation' is gaining traction as consumers become more health-conscious, paving the way for new entrants in this segment.

The growth trends within this segment highlight the increasing adoption of 'Nutritional Supplementation' as an alternative for dry AMD management. Factors such as rising awareness about ocular health, coupled with technological advancements in supplementation formulations, are driving this change. Furthermore, the market is supported by a well-established infrastructure for pharmacological therapies, ensuring that patients have access to effective treatment regimens, which continues to shape market dynamics in favor of pharmacological methods while positioning nutritional options as an emerging player.

Pharmacological (Dominant) vs. Nutritional Supplementation (Emerging)

Pharmacological treatments dominate the South America AMD market, including FDA-approved medications that are widely recognized for their efficacy in slowing disease progression. These treatments are characterized by extensive clinical research and a strong endorsement from healthcare professionals, which solidifies their place in treatment protocols. However, 'Nutritional Supplementation' is evolving rapidly, driven by an increase in preventive health measures among the population. Supplementation products are often viewed as complementary therapies, focusing on maintaining retinal health and providing essential nutrients. This segment appeals primarily to health-savvy consumers, positioning nutraceuticals as a significant emerging sector. The combination of established pharmacological treatments and the growth of nutritional options reflects a changing landscape in the management of dry AMD.

### By Stage of Disease: Intermediate Stage (Largest) vs. Late Stage (Fastest-Growing)

In the South America Dry Age Related Macular Degeneration (AMD) market, the distribution of segments by stage of disease reveals significant insights. The intermediate stage currently commands the largest market share, benefiting from the increased prevalence of AMD among the aging population. Conversely, the late stage, though smaller in overall share, shows marked growth potential as awareness of advanced AMD treatments rises, coupled with an increase in the aging demographic advocating for early detection and intervention.

Intermediate Stage (Dominant) vs. Late Stage (Emerging)

The intermediate stage of AMD is characterized by notable vision impairment but still retains some functional capabilities, making it essential for treatment strategies in South America. Those affected in this stage are likely to require regular monitoring and management, resulting in robust demand for ophthalmic interventions. On the other hand, the late stage represents an emerging segment with higher growth potential, driven by a surge in advanced treatment options now available. Patients in this stage face significant vision loss, prompting a rapid adoption of therapeutic innovations. The focus on late-stage management is rising, driven by healthcare initiatives that encourage proactive treatment and research advancements, which promise a brighter outlook for affected individuals.

## Regional Market Share Analysis

### Brazil : Robust Growth and Innovation

Brazil holds a commanding market share of 44.1% in the Dry Age Related Macular Degeneration (AMD) market, valued at $180.0 million. Key growth drivers include an aging population, increasing awareness of eye health, and advancements in treatment options. Government initiatives, such as the National Health System's support for ophthalmic care, further bolster demand. Infrastructure improvements in healthcare facilities enhance access to treatments, driving consumption patterns toward innovative therapies.

### Mexico : Growing Demand for Eye Care

Mexico accounts for 22.1% of the South American AMD market, valued at $90.0 million. The growth is driven by rising healthcare expenditure and increasing prevalence of AMD among the elderly. Demand trends indicate a shift towards preventive care and early diagnosis, supported by government health campaigns. Regulatory policies are evolving to facilitate faster drug approvals, enhancing market dynamics and encouraging investment in the sector.

### Argentina : Focus on Patient-Centric Care

Argentina represents 17.3% of the AMD market in South America, valued at $70.0 million. Key growth drivers include a growing elderly population and increased healthcare awareness. The government has implemented policies to improve access to ophthalmic treatments, fostering a favorable environment for market expansion. Demand for innovative therapies is rising, reflecting changing consumption patterns among patients seeking effective solutions.

### Rest of South America : Diverse Needs and Solutions

The Rest of South America holds a market share of 10.2%, valued at $40.8 million. This sub-region includes countries like Chile and Colombia, where the demand for AMD treatments is gradually increasing. Growth is driven by rising awareness and healthcare investments. Local governments are focusing on improving healthcare infrastructure, which is crucial for market development. The competitive landscape features both local and international players, creating a dynamic business environment.

## Competitive Benchmarking

The Dry Age-Related Macular Degeneration Market in South America is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Novartis (CH), Roche (CH), and Regeneron Pharmaceuticals (US) are actively pursuing strategies that emphasize research and development, aiming to enhance their product offerings and market presence. Novartis (CH) has focused on expanding its portfolio through collaborations with local healthcare providers, which appears to enhance its distribution capabilities. Meanwhile, Roche (CH) is investing heavily in digital transformation initiatives, aiming to leverage data analytics for better patient outcomes, thus positioning itself as a leader in personalized medicine. Regeneron Pharmaceuticals (US) is also notable for its commitment to innovation, particularly in the development of novel therapies that address unmet medical needs in the AMD space, which collectively shapes a competitive environment that is dynamic and responsive to market demands.

The business tactics employed by these companies reflect a nuanced understanding of the market's structure, which is moderately fragmented yet dominated by a few key players. Localizing manufacturing and optimizing supply chains are critical strategies that these companies are adopting to enhance operational efficiency and reduce costs. This localized approach not only mitigates risks associated with The Dry Age Related Macular Degeneration Amd changes, thereby strengthening their competitive positions.

In December 2025, Novartis (CH) announced a strategic partnership with a leading South American healthcare provider to enhance access to its AMD therapies. This collaboration is expected to facilitate better patient outreach and education, ultimately driving higher adoption rates of its innovative treatments. The strategic importance of this partnership lies in its potential to significantly increase Novartis's market share in a region where access to advanced therapies has been historically limited.

In November 2025, Roche (CH) launched a new digital health platform aimed at improving patient engagement and adherence to AMD treatment regimens. This initiative is particularly significant as it aligns with the growing trend of digitalization in healthcare, allowing Roche to gather real-time data on treatment efficacy and patient experiences. Such insights could inform future product development and marketing strategies, thereby enhancing Roche's competitive edge.

In October 2025, Regeneron Pharmaceuticals (US) received regulatory approval for a new AMD treatment that utilizes a novel mechanism of action. This approval is a pivotal moment for the company, as it not only diversifies its product portfolio but also positions Regeneron as a frontrunner in the innovation race within the AMD market. The strategic importance of this development cannot be overstated, as it may lead to increased revenue streams and bolster the company's reputation as a leader in AMD therapies.

As of January 2026, the competitive trends in the Dry Age Related Macular Degeneration Amd Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, it is likely that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in a market that is poised for continued growth.

## Recent News & Developments

Recent developments in the South America Dry Age-Related Macular Degeneration (AMD) Market have been significant as companies like Bayer, Genentech, and Novartis continue to focus on innovative treatment solutions. In August 2023, Bayer launched a new initiative aimed at increasing awareness and diagnosis of AMD in the region, particularly in Brazil and Argentina, where incidence rates are markedly high. Additionally, Roche's commitment to research and development has led to promising clinical trials for new therapies targeting dry AMD, showcasing their potential to enhance patient outcomes.

In terms of mergers and acquisitions, Novartis announced in July 2023 their acquisition of a smaller biotech firm focused on ocular treatments, which is anticipated to strengthen its portfolio within the AMD sector. Over the past couple of years, there has been notable growth in market valuation as investments in AMD treatment technologies have surged, reflecting increasing demand for effective therapies. This growth trend has been particularly evident in countries with aging populations, such as Chile and Uruguay, further driving interest from pharmaceutical companies and investors alike.

## Report Scope

| MARKET SIZE 2024 | 380.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 412.4(USD Million) |
| MARKET SIZE 2035 | 845.6(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.52% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novartis (CH), Roche (CH), Regeneron Pharmaceuticals (US), Bayer (DE), Allergan (IE), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US) |
| Segments Covered | Application, End User, Type of Treatment, Stage of Disease |
| Key Market Opportunities | Emerging telemedicine solutions enhance access to Dry Age Related Macular Degeneration Amd care in South America. |
| Key Market Dynamics | Rising prevalence of Dry Age Related Macular Degeneration drives demand for innovative treatment options in South America. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What is the projected market valuation for the South America Dry Age Related Macular Degeneration AMD market by 2035?**
A: The projected market valuation for the South America Dry Age Related Macular Degeneration AMD market is expected to reach 845.6 USD Million by 2035.

**Q: What was the overall market valuation for the South America Dry Age Related Macular Degeneration AMD market in 2024?**
A: The overall market valuation for the South America Dry Age Related Macular Degeneration AMD market was 380.8 USD Million in 2024.

**Q: What is the expected CAGR for the South America Dry Age Related Macular Degeneration AMD market during the forecast period 2025 - 2035?**
A: The expected CAGR for the South America Dry Age Related Macular Degeneration AMD market during the forecast period 2025 - 2035 is 7.52%.

**Q: Which companies are considered key players in the South America Dry Age Related Macular Degeneration AMD market?**
A: Key players in the market include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, Allergan, Santen Pharmaceutical, Horizon Therapeutics, and Apellis Pharmaceuticals.

**Q: What are the projected values for the Therapeutic Intervention segment by 2035?**
A: The projected value for the Therapeutic Intervention segment is expected to reach 325.6 USD Million by 2035.

**Q: How does the market for Clinical Diagnosis compare between 2024 and 2035?**
A: The market for Clinical Diagnosis increased from 95.2 USD Million in 2024 to a projected 215.0 USD Million by 2035.

**Q: What is the expected market size for Ophthalmology Clinics by 2035?**
A: The expected market size for Ophthalmology Clinics is projected to reach 220.0 USD Million by 2035.

**Q: What are the anticipated values for the Late Stage segment by 2035?**
A: The anticipated value for the Late Stage segment is expected to be 332.8 USD Million by 2035.

**Q: What is the projected market size for Nutritional Supplementation by 2035?**
A: The projected market size for Nutritional Supplementation is expected to reach 180.0 USD Million by 2035.

**Q: How does the market for Home Care Settings evolve from 2024 to 2035?**
A: The market for Home Care Settings is expected to grow from 80.8 USD Million in 2024 to 175.6 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-dry-age-related-macular-degeneration-market-44900*